Structures by: Aakeröy C. B.
Total: 489
(3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)4-COOH
(C10H8N4)(C6H10O4)
CrystEngComm (2013) 15, 3 463
a=5.2025(4)Å b=7.0703(6)Å c=11.4579(10)Å
α=99.247(5)° β=102.957(6)° γ=101.395(5)°
03-04BD (3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)6-COOH
(C10H8N4)(C8H14O4)
CrystEngComm (2013) 15, 3 463
a=5.4680(6)Å b=7.0381(7)Å c=11.9358(12)Å
α=98.867(6)° β=93.592(6)° γ=102.392(6)°
05:04BD (4-pyridyl)-N=N-(4-pyridyl), HOOC-(CH2)6-COOH
(C10H8N4)(C8H14O4)
CrystEngComm (2013) 15, 3 463
a=5.8269(6)Å b=8.6817(8)Å c=9.0827(9)Å
α=76.314(6)° β=87.963(6)° γ=77.486(6)°
MS 9-37 1,3,5-tri(C(CN)=NOH)benzene, 1,4-di(4-pyridyl)ethane
(C12H6N6O3)2(C12H12N2)3(C2H3N)2.25
CrystEngComm (2012) 14, 1 71
a=11.310(2)Å b=17.162(3)Å c=17.335(3)Å
α=88.010(10)° β=82.742(10)° γ=70.891(10)°
C7H7ClCuNO2
C7H7ClCuNO2
Journal of the Chemical Society, Dalton Transactions (2000) 21 3869
a=3.8105(16)Å b=15.819(7)Å c=13.311(6)Å
α=90.00° β=96.045(7)° γ=90.00°
C7H7CuINO2
C7H7CuINO2
Journal of the Chemical Society, Dalton Transactions (2000) 21 3869
a=4.0964(11)Å b=13.656(5)Å c=16.114(5)Å
α=90.00° β=92.225(6)° γ=90.00°
Bis(2-amino-4-(3-pyridyl)-6-methylpyrimidine) mu- (OAc)4dicopper(ii)
(C10H10N4)2Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.0282(5)Å b=10.6399(7)Å c=18.9041(13)Å
α=90.00° β=99.3600(10)° γ=90.00°
Bis(2-amino-4-(3-pyridyl)-6-methoxypyrimidine) mu-(OAc)4 dicopper(ii)
(C10H10N4O)2Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.2800(6)Å b=9.3983(6)Å c=11.2233(7)Å
α=71.144(4)° β=81.585(4)° γ=79.240(4)°
(2-amino-4-(3-pyridyl)-6-methoxypyridine)2, (2- fluorobenzoate)4 Cu2
(C10H10N4O1)2(C7H4O2F)4Cu2
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=10.1310(9)Å b=10.5499(8)Å c=12.2936(9)Å
α=64.853(5)° β=86.149(5)° γ=67.896(4)°
1-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (CH3COO)4Cu2
(C12H9N3)Cu2(C2H3O2)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=8.1368(11)Å b=8.3062(11)Å c=8.7490(12)Å
α=86.244(3)° β=80.480(3)° γ=80.539(3)°
1-(2-NH2-5-pyridyl)-2-(3-pyridyl)-ethyne, (2FPhCOO)4Cu2
(C12H9N3)Cu2(C7H4O2F)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=9.3471(9)Å b=15.5850(15)Å c=12.9025(11)Å
α=90.00° β=104.714(7)° γ=90.00°
1-(2-NH2-4-pyrimidyl)-2-(3-methoxy-5-pyridyl)ethyne (AcO)4Cu2 (EtO).6 (CH3CN).8
(C34H36Cu2N8O10)(C2H5O)0.6(C2H3N)0.8
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=7.6304(13)Å b=11.3870(19)Å c=12.341(2)Å
α=76.216(3)° β=84.191(3)° γ=79.459(3)°
Bis(4-((6,7-dimethylbenzimidazol-1-yl)methyl)benzamide), AgBF4
(C17H17N3O)2Ag(BF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.9140(7)Å b=8.4229(6)Å c=19.7055(13)Å
α=90.00° β=102.108(3)° γ=90.00°
(4-((5,6-dimethylbenzimidazol-1-yl)methyl)benzamide)2, AgAsF6
(C17H17N3O)2AgAsF6
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.1269(6)Å b=9.2459(5)Å c=10.0615(7)Å
α=97.921(4)° β=89.950(4)° γ=98.904(4)°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.3084(4)Å b=18.5828(11)Å c=25.1620(15)Å
α=90.00° β=96.8060(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-4-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)(O)3
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=7.5069(5)Å b=18.6924(12)Å c=24.9808(17)Å
α=90.00° β=98.4920(10)° γ=90.00°
Bis(2-methyl-3-((benzamide-3-yl)methyl)benzimidaol-1- yl)silver(i) (SbF6)
(C16H15N3O)2Ag(SbF6)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=9.2644(4)Å b=13.2045(6)Å c=14.2022(6)Å
α=74.5580(10)° β=81.7510(10)° γ=72.2750(10)°
Bis(4-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4, H2O
(C16H15N3O)2(AgBF4)(O)3.4
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=40.141(3)Å b=4.9633(5)Å c=18.6857(19)Å
α=90.00° β=96.855(6)° γ=90.00°
3-((2-methylbenzimidazol-1-yl)methyl)benzamide, Ag (AsF6)
(C16H15N3O)2Ag(AsF6)(CH4O)0.5
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.8443(8)Å b=12.1157(7)Å c=13.3329(8)Å
α=66.333(3)° β=69.670(3)° γ=87.960(3)°
?DW-X-7-SEB 2-amino-5-(iodoethynyl)-pyrimidine
C6H4IN3
CrystEngComm (2017) 19, 1 11
a=7.6148(9)Å b=7.8988(8)Å c=24.473(3)Å
α=90.00° β=90.00° γ=90.00°
DW-Y-2 2-amino-5-ethynylpyrimidine
C6H5N3
CrystEngComm (2017) 19, 1 11
a=4.3404(7)Å b=7.7073(12)Å c=8.6344(15)Å
α=90.00° β=91.363(9)° γ=90.00°
DW-X-8-DOD [2-amino-5-(iodoethynyl)-pyrimidine]2, 2,3,5,6-Me4-pyrazine
(C6H4IN3)2(C8H12N2)
CrystEngComm (2017) 19, 1 11
a=5.7837(5)Å b=6.1130(5)Å c=16.4016(14)Å
α=98.086(4)° β=92.180(4)° γ=101.892(4)°
DW-Y-8 (2-amino-5-ethynylpyrimidine)2, 2,3,5,6-Me4-pyrazine
(C6H5N3)2(C8H12N2)
CrystEngComm (2017) 19, 1 11
a=5.7849(18)Å b=6.0656(18)Å c=14.756(5)Å
α=79.742(8)° β=88.831(8)° γ=80.342(7)°
DW-X-4 [2-amino-5-(iodoethynyl)-pyrimidine]2, 1,2-bis(4-pyridyl)ethylene
(C6H4IN3)2(C12H10N2)
CrystEngComm (2017) 19, 1 11
a=19.625(2)Å b=7.5472(7)Å c=8.2583(8)Å
α=90.00° β=100.950(4)° γ=90.00°
DW-Y-4 2-amino-5-ethynylpyrimidine, (1,2-bis(4-pyridyl)ethylene)2
(C6H5N3)2(C12H10N2)
CrystEngComm (2017) 19, 1 11
a=5.9068(6)Å b=11.5286(12)Å c=15.8169(16)Å
α=104.471(4)° β=93.042(5)° γ=95.934(4)°
Mp-p1B-H5 F5-I-benzene, [1,2,3]Triazolo[1,5-a]quinoline
(C6F5I)(C10H7N3)
CrystEngComm (2016) 18, 44 8631
a=7.8304(9)Å b=15.1834(18)Å c=12.9152(15)Å
α=90.00° β=103.176(5)° γ=90.00°
Mp-p1b-Hb7 1,4-diiodotetrafluorobenzene, ([1,2,3]Triazolo[1,5-a]quinoline)2
(C6F4I2)(C10H7N3)2
CrystEngComm (2016) 18, 44 8631
a=6.6906(14)Å b=9.568(2)Å c=10.618(2)Å
α=64.954(6)° β=79.728(5)° γ=87.328(5)°
Mp-p1b-H11 {[1,2,3]Triazolo[1,5-a]quinoline}2, HOOC-(CH2)4-COOH
(C10H7N3)2(C6H10O4)
CrystEngComm (2016) 18, 44 8631
a=6.9843(6)Å b=25.501(2)Å c=6.8129(6)Å
α=90.00° β=108.111(4)° γ=90.00°
Mp-p1b-H21 [1,2,3]Triazolo[1,5-a]quinoline, 2-F-PhCOOH
(C10H7N3)(C7H5O2F)
CrystEngComm (2016) 18, 44 8631
a=6.3976(15)Å b=20.616(5)Å c=10.876(3)Å
α=90.00° β=98.126(9)° γ=90.00°
Mp-p1b-H15 {[1,2,3]Triazolo[1,5-a]quinoline}2, HOOC-(CH2)3-COOH
(C10H7N3)2(C5H8O4)
CrystEngComm (2016) 18, 44 8631
a=28.065(11)Å b=36.966(14)Å c=4.2708(16)Å
α=90.00° β=90.00° γ=90.00°
Mp-p1b-H24 {[1,2,3]Triazolo[1,5-a]quinoline}2, 4-I-F4-PhCOOH
(C10H7N3)2(C7HF4IO2)
CrystEngComm (2016) 18, 44 8631
a=6.6580(8)Å b=9.8155(11)Å c=10.4663(13)Å
α=65.256(4)° β=79.993(4)° γ=84.833(4)°
EK-B-Mal (3-pyridyl)-CONH-N=CH-(4-pyridyl), HOOC-(CH2)-COOH
(C12H10N4O)(C3H4O4)
CrystEngComm (2017)
a=7.0290(10)Å b=10.5537(15)Å c=10.8826(15)Å
α=73.431(5)° β=76.424(5)° γ=71.357(5)°
EK-A-Pim (2-pyridyl)-CONH-N=CH-(3-pyridyl), HOOC-(CH2)5-COOH
(C12H10N4O)(C7H12O4)
CrystEngComm (2017)
a=5.5981(7)Å b=45.389(5)Å c=7.3036(8)Å
α=90.00° β=98.469(5)° γ=90.00°
EK-D-Sub [(4-pyridyl)-CONH-N=CH-(2-pyridyl)]2, HOOC-(CH2)6-COOH dihydrate
(C12H10N4O)2(C8H14O4)(H2O)2
CrystEngComm (2017)
a=6.6774(11)Å b=8.2196(14)Å c=15.972(3)Å
α=81.888(7)° β=83.771(8)° γ=74.805(7)°
EK-B-Glu (3-pyridyl)-CONH-N=CH-(4-pyridyl), HOOC-(CH2)3-COOH dihydrate
(C12H10N4O)(C5H8O4)(H2O)2
CrystEngComm (2017)
a=10.9929(10)Å b=11.4742(10)Å c=16.1087(14)Å
α=102.095(3)° β=108.567(4)° γ=95.615(3)°
EK-B-Suc 3-pyridyl-CONH-N=CH-(3-pyridyl), HOOC-(CH2)2-COOH
(C12H10N4O)(C4H6O4)(H2O)
CrystEngComm (2017)
a=7.1160(8)Å b=13.0840(16)Å c=36.062(5)Å
α=90.00° β=90.00° γ=90.00°
EK-D-Adp [(4-pyridyl)-CONH-N=CH-(2-pyridyl)]2, HOOC-(CH2)4-COOH dihydrate
(C12H10N4O)2(C6H10O4)(H2O)2
CrystEngComm (2017)
a=6.5986(6)Å b=8.0173(8)Å c=15.3396(14)Å
α=97.862(4)° β=101.861(3)° γ=104.541(3)°
EK-A-Azl (2-pyridyl)-CONH-N=CH-(3-pyridyl), HOOC-(CH2)7-COOH
(C12H10N4O)(C9H16O4)
CrystEngComm (2017)
a=8.5041(12)Å b=9.6723(14)Å c=14.013(2)Å
α=80.742(6)° β=81.368(6)° γ=68.770(5)°
EK-C-Dod (3-pyridyl)-CONH-N=CH-(3-pyridyl), HOOC-(CH2)10-COOH hydrate
(C12H10N4O)(C12H22O4)(H2O)
CrystEngComm (2017)
a=6.9300(8)Å b=7.8773(10)Å c=24.680(3)Å
α=85.562(6)° β=83.394(6)° γ=66.198(5)°
EK-C-Seb (3-pyridyl)-CONH-N=CH-(3-pyridyl), HOOCH-(CH2)8-COOH hydrate
(C12H10N4O)(C10H18O4)(H2O)
CrystEngComm (2017)
a=6.9504(10)Å b=14.170(2)Å c=23.788(3)Å
α=79.555(9)° β=84.610(8)° γ=89.821(9)°
EK-D-Azl [(4-pyridyl)-CONH-N=CH-(2-pyridyl)]2, HOOC-(CH2)7-COOH dihydrate
(C12H10N4O)2(C9H16O4)(H2O)2
CrystEngComm (2017)
a=36.802(8)Å b=7.2815(14)Å c=12.533(3)Å
α=90.00° β=92.978(8)° γ=90.00°
EK-A-Glu (2-pyridyl)-CONH-NHCO-(3-pyridyl), HOOC-(CH2)3-COOH
(C12H10N4O)(C5H8O4)
CrystEngComm (2017)
a=20.694(3)Å b=5.5714(8)Å c=14.954(2)Å
α=90.00° β=105.047(7)° γ=90.00°
EK-A-Mal (2-pyridyl)-CONH-N=CH-(3-pyridyl), HOOC-(CH2)1-COOH
(C12H10N4O)(C3H4O4)
CrystEngComm (2017)
a=8.0953(12)Å b=9.9439(14)Å c=10.1459(15)Å
α=99.924(6)° β=106.674(6)° γ=100.865(6)°
BS-II-U-69 2,3,5,6-Me4-pyrazine-1-oxide, urea
C8H12N2O,CH4N2O
Chemical communications (Cambridge, England) (2018) 54, 37 4657-4660
a=12.646(13)Å b=7.002(7)Å c=22.75(2)Å
α=90.00° β=90.00° γ=90.00°
C22H14CuF12N4O6
C22H14CuF12N4O6
Dalton transactions (Cambridge, England : 2003) (2019)
a=8.7980(14)Å b=9.4558(18)Å c=9.9430(15)Å
α=86.776(15)° β=73.162(14)° γ=63.012(18)°
C10H12O2,H2O
C10H12O2,H2O
New Journal of Chemistry (2018) 42, 13 10539
a=9.9472(12)Å b=6.1399(8)Å c=16.775(2)Å
α=90° β=104.248(2)° γ=90°
TW-2B-8-C 1,1'-di[(2-pyridyl)methyl]-2,2'-biimidazole, [HOOC-(CH2)5-COOH]2
(C18H16N6)(C7H12O4)2
New J. Chem. (2015) 39, 2 822
a=4.9161(10)Å b=8.0077(16)Å c=20.828(4)Å
α=87.266(11)° β=88.665(10)° γ=72.608(9)°
2-amino-4-(6-methoxy-3-pyridyl)-6-methylpyrimidine, 4-(Me2N)-PhCOOH
(C11H12N4O)(C9H11NO2)
New Journal of Chemistry (2006) 30, 10 1452
a=7.8442(12)Å b=8.8879(14)Å c=14.216(2)Å
α=101.607(2)° β=90.830(2)° γ=106.753(2)°
[1-(3-OMe-5-pyridyl)-2-(2-amino-4-methyl-6-pyrimidyl)-ethyne], NO2PhCOOH
(C13H12N4O)(C7H5NO4)
New Journal of Chemistry (2006) 30, 10 1452
a=6.9157(12)Å b=6.9405(12)Å c=19.854(4)Å
α=87.646(3)° β=80.636(3)° γ=81.138(3)°
2-(4-pyridyl)-imidazole, silver(I) hexafluorophosphate
(C8H7N3)(AgPF6)(C2H3N)
New Journal of Chemistry (2013) 37, 1 204
a=6.7927(3)Å b=15.7016(7)Å c=13.1938(6)Å
α=90.00° β=102.723(2)° γ=90.00°
TW-Pyr-bis-N-oxide 2,3,5,6-Me4-pyrazine-1,4-dioxideC8 H12 N2 O2
C8H12N2O2
Chemical communications (Cambridge, England) (2015) 51, 12 2425-2428
a=3.8328(9)Å b=10.291(3)Å c=10.396(3)Å
α=90.00° β=98.770(9)° γ=90.00°
4-bromo-PhC(CN)(N=OH), (3-((5,6-dimethylbenzimidazol-1- yl)methyl)PhCN
(C8H5N2OBr)(C17H15N3)
CrystEngComm (2009) 11, 3 439-443
a=6.039(3)Å b=13.982(6)Å c=14.166(6)Å
α=70.067(19)° β=83.78(3)° γ=82.22(3)°
D8 2-aminopyrazine, HOOC-(CH2)3-COOH
(C4H5N3)(C5H8O4)
CrystEngComm (2012) 14, 18 5845
a=5.2487(3)Å b=29.2633(18)Å c=7.2357(5)Å
α=90.00° β=104.958(3)° γ=90.00°
SF41 4-pyridyl-CONH-N=CH-4-pyridyl, succinic acid dihydrate
(C12H10N4O)(C4H6O4)(H2O)2
CrystEngComm (2012) 14, 7 2435
a=4.8122(3)Å b=8.8128(5)Å c=11.0772(6)Å
α=75.874(3)° β=80.095(3)° γ=76.225(3)°
242 (3-pyridyl)-CONH-N=CH-(2-pyridyl), hexanoic acid hydrate
(C12H10N4O)(C6H12O2)(H2O)
CrystEngComm (2012) 14, 7 2435
a=6.6573(13)Å b=8.1256(14)Å c=18.128(3)Å
α=95.391(10)° β=97.999(12)° γ=104.439(14)°
3,3'-AzoPy 4-HBXB, (3-pyridyl)-N=N-(3-pyridyl), (4-Br-F4- PhOH)2
(C10H8N4)(C6HBrF4O)2
CrystEngComm (2013) 15, 16 3125
a=18.2149(8)Å b=16.4379(7)Å c=7.4736(4)Å
α=90.00° β=99.631(2)° γ=90.00°
3,3'-AzoPy 5-HBXB (3-pyridyl)-N=N-(3-pyridyl), (4-Br-F4-PhCHO oxime)2
(C10H8N4)(C7H2BrF4NO)2
CrystEngComm (2013) 15, 16 3125
a=8.3500(8)Å b=8.3646(8)Å c=9.8996(10)Å
α=105.765(3)° β=103.151(3)° γ=99.733(3)°
4,4'-AzoPy 4-HBXB (4-pyridyl)-N=N-(4-pyridyl), 4-Br-F4-PhOH
(C10H8N4)(C6HBrF4O)
CrystEngComm (2013) 15, 16 3125
a=6.3706(3)Å b=9.5670(5)Å c=13.3289(7)Å
α=79.453(2)° β=83.090(2)° γ=79.4760(10)°
C17H9BrF4N4O2
C17H9BrF4N4O2
CrystEngComm (2013) 15, 16 3125
a=10.1601(6)Å b=13.4584(8)Å c=14.4512(10)Å
α=112.181(4)° β=90.560(4)° γ=111.547(4)°
03-03BD (3-pyridyl)-N=N-(3-pyridyl), HOOC-(CH2)8-COOH
(C10H8N4)(C10H18O4)
CrystEngComm (2013) 15, 3 463
a=7.0388(14)Å b=8.2451(18)Å c=17.490(4)Å
α=77.525(14)° β=80.368(13)° γ=85.474(14)°
(2-amino-4-(3-pyridyl)-6-methylpyridine)2, (2FPhCOO)4 Cu2
(C10H10N4)2Cu2(C7H4O2F)4
Dalton transactions (Cambridge, England : 2003) (2006) 13 1627-1635
a=21.3553(18)Å b=17.9389(15)Å c=11.4887(9)Å
α=90.00° β=90.742(5)° γ=90.00°
Bis(3-((2-methylbenzimidazol-1-yl)methyl)benzamide) silver(i) BF4
(C16H15N3O)2(AgBF4)
Dalton transactions (Cambridge, England : 2003) (2005) 14 2462-2470
a=11.666(2)Å b=12.237(2)Å c=13.013(2)Å
α=109.136(13)° β=114.266(8)° γ=92.310(14)°
Mp-p1b-H10 [1,2,3]Triazolo[1,5-a]quinoline
C10H7N3
CrystEngComm (2016) 18, 44 8631
a=10.9465(10)Å b=8.6731(8)Å c=50.527(5)Å
α=90.00° β=93.861(4)° γ=90.00°
Mp-p1b-H28 [1,2,3]triazolo[1,5-a]pyridine, 1,2-diiodotetrafluorobenzene
(C6H5N3)(C6F4I2)
CrystEngComm (2016) 18, 44 8631
a=8.1237(17)Å b=7.1542(15)Å c=12.318(3)Å
α=90° β=92.502(7)° γ=90°
EK-A-Adp [2-pyridyl-CONH-N=CH-(3-pyridyl)]2, HOOC-(CH2)4-COOH
(C12H10N4O)2(C6H10O4)
CrystEngComm (2017)
a=5.9660(5)Å b=7.2613(6)Å c=16.8960(14)Å
α=89.858(2)° β=80.013(3)° γ=79.638(2)°
A-2-6 CVT-COOH, 4,4'-bipyridyl
(C60H72O16)(C10H8N2)2(C2H3N)0.8(CH3OH)2(CH3O)1.2
CrystEngComm (2016) 18, 39 7457
a=29.225(3)Å b=11.4565(11)Å c=23.889(2)Å
α=90° β=99.091(5)° γ=90°
A-2-4 HOOC-CVT, 2-H2N-4-Cl-5-Br-6-H3C-pyrimidine
(C60H72O16)2(C5H5N3BrCl)3(H2O)4(C2H3N)8
CrystEngComm (2016) 18, 39 7457
a=14.7508(9)Å b=16.1947(10)Å c=17.6138(11)Å
α=75.197(2)° β=79.775(3)° γ=80.709(3)°
Copper(ii)(isonicotinamide)diacetate
(C10H12Cu1N2O5)(C2H3N)
Dalton Trans. (2003) 20 3956-3962
a=7.1996(10)Å b=8.1027(12)Å c=13.4485(19)Å
α=90.408(2)° β=96.328(3)° γ=96.118(2)°
Copper(ii)bis(isonicotinamide)bis(2-fluorobenzoate)
C26H24CuF2N4O8
Dalton Trans. (2003) 20 3956-3962
a=7.4814(12)Å b=7.7279(14)Å c=12.586(2)Å
α=72.762(3)° β=72.803(3)° γ=77.970(3)°
Copper(ii)(isonicotinamide)diacetate
C16H18CuN4O6,C1H4O,(C1H4O)0.25
Dalton Trans. (2003) 20 3956-3962
a=9.3053(17)Å b=10.1542(19)Å c=12.885(2)Å
α=69.735(3)° β=75.696(3)° γ=67.129(3)°
Copper(ii)bis(isonicotinamide)diacetate diacetic acid
C16H18CuN4O6,(C2H4O2)2
Dalton Trans. (2003) 20 3956-3962
a=11.0398(15)Å b=15.245(2)Å c=15.650(2)Å
α=90.00° β=104.910(3)° γ=90.00°
Bis(isonicotinamide)-bis(2-fluorobenzoate)(2-fluorobenzoic acid)copper(ii)
(C6H6N2O)2(C7H4O2F)2(C7H5O2F)Cu
Dalton Trans. (2003) 20 3956-3962
a=11.0792(14)Å b=19.771(2)Å c=15.5280(19)Å
α=90.00° β=104.284(3)° γ=90.00°
AS-15 2-(4-tolyl)-2,4-pentanedione
C12H14O2
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=7.5220(8)Å b=6.6202(7)Å c=11.1582(12)Å
α=90.00° β=108.875(4)° γ=90.00°
AS-14 2-(4-chlorophenyl)-2,4-pentanedione
C11H11ClO2
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=20.2258(14)Å b=6.7622(5)Å c=7.3688(5)Å
α=90.00° β=90.00° γ=90.00°
AS-5 2-(4-bromophenyl)-2,4-pentanedione
C11H11BrO2
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=20.4766(18)Å b=6.8070(6)Å c=7.3506(6)Å
α=90.00° β=90.00° γ=90.00°
PC-7-3-Iacac 2-(4-iodophenyl)-2,4-pentanedione
C11H11IO2
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=21.0708(12)Å b=6.9034(4)Å c=7.3624(4)Å
α=90.00° β=90.00° γ=90.00°
AS-12 2-(4-tolyl)-2,4-pentanedione, copper(II) tetrafluoroborate
(C12H13O2)2Cu
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=11.9427(6)Å b=16.3128(8)Å c=21.4984(11)Å
α=90.00° β=90.00° γ=90.00°
AS-6 bis[2-(4-bromophenyl)-2,4-pentanedionato]copper(II)
(C11H10BrO2)2(Cu)
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=12.0389(11)Å b=15.8409(12)Å c=22.1627(17)Å
α=90.00° β=90.00° γ=90.00°
D1 bis[2-(4-chlorophenyl)-2,4-pentanedionato]copper(II)
(C11H10ClO2)2Cu
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=11.9763(7)Å b=15.8265(9)Å c=21.7849(11)Å
α=90.00° β=90.00° γ=90.00°
AS-10 2-(4-iodophenyl)-2,4-pentanedione, copper(II) nitrate
(C11H10IO2)2Cu
Dalton transactions (Cambridge, England : 2003) (2011) 40, 45 12160-12168
a=8.2510(4)Å b=7.7262(4)Å c=17.8085(10)Å
α=90.00° β=101.525(3)° γ=90.00°
C18H18AgBF4N6O3
C18H18AgBF4N6O3
Journal of the Chemical Society, Dalton Transactions (1998) 12 1943
a=6.9461(6)Å b=18.108(2)Å c=16.897(2)Å
α=90.00° β=97.880(6)° γ=90.00°
C18H18AgClN6O7
C18H18AgClN6O7
Journal of the Chemical Society, Dalton Transactions (1998) 12 1943
a=6.9240(5)Å b=18.1992(15)Å c=16.9880(15)Å
α=90.00° β=98.052(6)° γ=90.00°
2(C6H6N2O),C6F4I2
2(C6H6N2O),C6F4I2
Chemical Communications (Cambridge, United Kingdom) (2007) 41 4236-4238
a=20.247(3)Å b=5.0710(9)Å c=21.279(3)Å
α=90.00° β=106.911(6)° γ=90.00°
621 4-carboxy-PhC(CN)=NOH, 1-((4-pyridyl)methyl)-5,6-Me2- benzimidazole
(C9H6N2O3)(C15H15N3)
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=11.0553(13)Å b=7.3121(9)Å c=13.2662(17)Å
α=90.00° β=94.693(7)° γ=90.00°
1-((4-pyridyl)methyl)-2-phenylimidazole, 4-hydroxybenzoic acid
(C15H13N3)(C7H6O3)
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=8.0137(8)Å b=9.8024(9)Å c=12.0784(13)Å
α=82.364(6)° β=86.045(7)° γ=75.888(6)°
442 1-((4-pyridyl)methyl)-5,6-dimethylbenzimidazole, 4- bromoPhC(CN)(=NOH)
C23H20BrN5O
Chemical communications (Cambridge, England) (2007) 38 3936-3938
a=15.9510(15)Å b=5.9914(6)Å c=23.071(2)Å
α=90.00° β=103.494(4)° γ=90.00°
(4-bromo-PhC(CN)(=NOH)), 3-bromo-5-methoxypyridine
(C8H5BrN2O)(C6H6BrNO)
CrystEngComm (2009) 11, 3 439-443
a=6.9907(6)Å b=8.0552(7)Å c=15.3027(13)Å
α=79.305(5)° β=89.038(5)° γ=64.660(5)°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)-2- methylbenzimidazole
(C8H5BrN2O)(C15H13BrN2)
CrystEngComm (2009) 11, 3 439-443
a=4.9374(6)Å b=22.597(3)Å c=19.233(2)Å
α=90.00° β=96.869(2)° γ=90.00°
(4-bromo-PhC(CN)(=NOH)), 1-(4-bromobenzyl)benzimidazole
(C8H5BrN2O)(C14H11BrN2)
CrystEngComm (2009) 11, 3 439-443
a=5.3033(6)Å b=13.2294(15)Å c=15.0601(17)Å
α=102.536(2)° β=99.505(2)° γ=94.752(2)°
(2-fluoro-PhC(CN)(=NOH))2, 1,2-di(4-pyridyl)ethene
(C8H5N2OF)2(C12H10N2)
CrystEngComm (2009) 11, 3 439-443
a=3.8189(6)Å b=11.2941(18)Å c=14.107(2)Å
α=98.884(10)° β=93.147(11)° γ=94.624(10)°
4-bromo-PhC(CN)(N=OH), (3-((5,6-dimethylbenzimidazol-1- yl)methyl)PhCN
(C8H5N2OBr)(C17H15N3)
CrystEngComm (2009) 11, 3 439-443
a=6.039(3)Å b=13.982(6)Å c=14.166(6)Å
α=70.067(19)° β=83.78(3)° γ=82.22(3)°
481 1,4-di((1-benzimidazolyl)methyl)benzene, (3-chloro- PhC(CN)(=NOH))2
(C22H18N4)(C8H5N2OCl)2
CrystEngComm (2009) 11, 3 439-443
a=13.6335(10)Å b=4.4402(3)Å c=27.297(2)Å
α=90.00° β=94.084(3)° γ=90.00°
MS 512 1-(4-pyridylmethyl)-5,6-Me2benzimidazole, 4-F- PhC(CN)(NOH)
(C15H15N3)(C8H5N2OF)
CrystEngComm (2009) 11, 3 439-443
a=16.1659(12)Å b=6.4146(5)Å c=21.0074(16)Å
α=90.00° β=105.945(5)° γ=90.00°
CVT-53-B2 bromo pentyl ethylene cavitand
(C56H68Br4O8)2(C2H3N1)5
CrystEngComm (2014) 16, 18 3796
a=14.9430(6)Å b=17.0436(7)Å c=26.1853(11)Å
α=101.948(2)° β=97.566(2)° γ=111.014(2)°
CJ-1 ethano 3-pyridyl CVT, (ethanol)9
(C76H84N4O8)2(C2H6O)9
CrystEngComm (2014) 16, 18 3796
a=12.7536(6)Å b=13.7525(7)Å c=24.5901(12)Å
α=105.279(2)° β=95.784(2)° γ=102.120(2)°
P-1-5 [tetra(3-pyridyl) CVT]2, (4-NO2-PhCOOH)8 (PhNO2)5 (H2 O)2
(C76H84N4O8)2(C7H5NO4)8(C6H5NO2)5(H2O)2
CrystEngComm (2014) 16, 18 3796
a=13.3210(9)Å b=52.697(4)Å c=16.3401(11)Å
α=90.00° β=109.773(3)° γ=90.00°
DW-10-7 (3-pyridyl)-CONH-(CH2)8-NHCO-(3-pyridyl), I-(CF2)2-I
(C20H26N4O2)(C2F4I2)
CrystEngComm (2014) 16, 44 10203
a=5.0587(4)Å b=5.0974(4)Å c=24.1635(19)Å
α=84.859(2)° β=84.330(2)° γ=88.194(2)°
DW-10-9 (3-pyridyl)-CONH-(CH2)8-NHCO-(3-pyridyl), I-(CF2)6-I
(C20H26N4O2)(C6F12I2)
CrystEngComm (2014) 16, 44 10203
a=5.0345(12)Å b=5.1049(12)Å c=29.113(7)Å
α=85.793(6)° β=87.469(7)° γ=88.033(5)°
DW-8-7 (3-pyridyl)-CONH-(CH2)6-NHCO-(3-pyridyl), I-(CF2)2-I
(C18H22N4O2)(C2F4I2)
CrystEngComm (2014) 16, 44 10203
a=5.0593(7)Å b=5.0774(7)Å c=22.229(3)Å
α=94.513(5)° β=91.986(4)° γ=91.522(4)°
DW-8-9 (3-pyridyl)-CONH-(CH2)6-NHCO-(3-pyridyl), I-(CF2)6-I
(C18H22N4O2)(C6F12I2)
CrystEngComm (2014) 16, 44 10203
a=64.445(6)Å b=4.9349(4)Å c=9.1473(8)Å
α=90.00° β=90.00° γ=90.00°